• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Check-Cap Ltd.

    11/4/25 5:16:13 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    6-K 1 ea0264017-6k_check.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    Commission File Number: 001-36848

     

    Check-Cap Ltd.

    (Exact Name of Registrant as Specified in Charter)

     

    Abba Hushi Avenue
    P.O. Box 1271
    Isfiya, 30090 Mount Carmel, Israel
    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-262401) and Form S-8 (File Nos. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Annual General Meeting of Shareholders – Rescheduling Notice

     

    Check-Cap Ltd. (the “Company”, or “Check-Cap”) has determined to reschedule its Annual General Meeting of Shareholders (“AGM”) originally scheduled for October 17, 2025. The AGM will be held on Friday, November 14, 2025, at 10:00 a.m., Eastern Time, at Paul Hastings LLP, 2050 M St NW, Washington, DC 20036, United States. A copy of the Notice of the Annual General Meeting of Shareholders, the Proxy Statement as well as the Proxy Card are attached as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, to the Form 6-K previously furnished with the U.S. Securities and Exchange Commission on September 12, 2025 and are incorporated herein by reference except that the proposed reverse split ratio in the Reverse Split Proposal (as defined below) will be within a range of 1 for 2 to 1 for 100, and the number of authorized ordinary shares will remain at 18,000,000 shares and the nominal value of the ordinary shares will remain at NIS 48.0 per share even if the Reverse Split Proposal is approved. All holders of record of the ordinary shares as of the close of business on September 16, 2025, the record date for the AGM, will be entitled to vote at the AGM. 

     

    Update on Proposed Business Combination

     

    On September 12, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MBody AI, a Nevada corporation (“MBody AI”), and CC Merger Sub Inc., a Nevada corporation and direct wholly owned subsidiary of Check-Cap (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub will merge with and into MBody AI, with MBody AI surviving as a wholly owned subsidiary of Check-Cap (such transaction, the “Merger”), forging a dynamic alliance set to generate enhanced shareholder value through market-leading advancements in embodied AI-driven automation.

     

    1

     

     

    MBody AI Business Update

     

    Since the announcement, MBody AI’s pipeline and active deployments have surged dramatically, propelled by significant inbound demand from premier clients in hospitality, logistics, and healthcare determined to capitalize on embodied-AI capabilities. This robust momentum has ignited a series of landmark multi-year contracts and strategic expansion dialogues with esteemed global brands. MBody AI is advancing with remarkable velocity, achieving swift progress in growth, customer integration, and commercial dominance, firmly establishing itself as a market-leader in embodied artificial intelligence technologies. Central to this ascent is the MBody AI Orchestrator, MBody AI’s innovative “Brains of Autonomy” AI stack, which empowers advanced, responsive robotic and embedded systems, transforming efficiencies across hospitality, warehousing, healthcare, and office management sectors.

     

    Institutional and strategic interest in MBody AI has escalated profoundly, attracting keen involvement from leading banks, prominent family offices, and elite global funds pursuing pre- and post-closing opportunities. Inbound investment inquiries have escalated to hundreds of millions of dollars, offering compelling third-party endorsement of MBody AI’s strengthened valuation and vigorous growth momentum. This outstanding performance and preeminent market stance have catalyzed a substantial elevation in MBody AI’s valuation, prompting both parties—after thorough deliberations with their boards, advisors, and investors—to optimize the transaction terms to encapsulate MBody AI’s amplified ambitions and bright prospects. In a significant advantage for shareholders, Check-Cap’s Board of Directors (the “Board”) is pleased to affirm that MBody AI is preserving the originally disclosed exchange ratio.

     

    Check-Cap is deeply satisfied to have secured MBody AI as its merger partner at this opportune moment. This calculated alignment situates shareholders at the forefront of one of the most profound transformations in today’s capital markets—embodied AI—widely acclaimed by visionary investment companies like Goldman Sachs and Morgan Stanley as a ‘once-in-a-generation category-defining breakthrough.’ By moving with precision and resolve, Check-Cap has acquired a partner that could have otherwise accessed public markets via rival avenues, such as high-profile IPOs or SPACs. MBody AI’s decision to partner with Check-Cap illuminates the unparalleled access now afforded to our shareholders: immersion in a rapid-ascension, pre-institutional narrative typically exclusive to top venture capital or private equity circles. This partnership provides public-market participants with a distinguished share in a venture during its high-growth surge, reflecting a collective dedication to forging a distinguished, publicly listed frontrunner in the domain.

     

    Check-Cap shareholders are ideally placed at the vanguard of a groundbreaking technological evolution. Embodied AI is spearheading what Morgan Stanley analysts characterize as a revolutionary wave akin to the internet, poised to generate trillions in AI-enabled economic impact.

     

    Through this timely union with MBody AI, Check-Cap grants its shareholders premium access to an industry anticipated to escalate from billions in current value to trillions by 2030 for AI robotics alone, with embodied systems potentially contributing to a $16 trillion market opportunity by 2050.

     

    2

     

     

    Investor Cathie Wood emphasizes that AI robots represent "the biggest of all the embodied AI opportunities," amplifying the strategic significance of MBody AI’s selection of Check-Cap and positioning their shareholders for a commanding role in the AI advancement landscape often reserved for industry elites.

     

    The Board is exceptionally proud to deliver this transaction to shareholders, representing the pinnacle of meticulous, multinational coordination by premier legal, audit, and investment banking experts. This refined architecture, developed under rigorous examination, exemplifies both entities’ capacity to execute pivotal corporate achievements with efficiency and precision.

     

    Next Steps and Meeting Purpose

     

    At the AGM, shareholders will be asked to consider and vote upon:

     

    1.Approval of the Merger Agreement to effect the Merger and other transactions in connection with the Merger;

     

    2.Approval of a reverse share split of the Company’s ordinary shares within a range of 1 for 2 to 1 for 100, the exact ratio to be determined by further action of the Board, to be effective on a date to be determined by the Board (the “Reverse Split Proposal”);

     

    3.Election of all four directors as members of the Board, each to serve until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified or their earlier resignation or removal; and

     

    4.Approval of the change of Check-Cap’s name to “MBody AI Ltd.” or a similar name approved by the Israeli Registrar of Companies, effective as of the effective time under the Merger Agreement and to amend the Articles of Association of the Company to reflect the name change.

     

    Subject to satisfaction or waiver of the closing conditions under the Merger Agreement, the parties expect to consummate the Merger in the weeks following shareholder approval. With the Merger approaching swift closure, the unified company is prepared to implement cross-listing and institutional alignment measures, elevating its standing among foremost global AI and robotics entities. Management firmly believes these actions will unlock considerable enhanced value for committed long-term shareholders.

     

    The Future is Now

     

    As the closing nears, Check-Cap shareholders should regard this as more than approving a merger—it is an invitation to stake a claim in the innovations of tomorrow. The emergent organization will emerge as a robust global AI authority, pursuing ambitious plans for additional cross-listing, index incorporation, and expansive international growth. Trailblazers in revolutionary technologies—from Amazon to Tesla to NVIDIA—have yielded remarkable returns. Today, Check-Cap shareholders possess that equivalent, compelling potential.

     

    Forward-Looking Statements

     

    This Report on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the anticipated timing and completion of the Merger, expected benefits of the Merger, the combined company’s business strategy and prospects, and other matters. These statements are based on current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, the risk that the conditions to closing are not satisfied, changes in market conditions, regulatory approvals, integration challenges, and general economic factors. The Company undertakes no obligation to update these statements, except as required by law.

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CHECK-CAP LTD.
      (Registrant)
       
    Date: November 4, 2025 By: /s/ David Lontini
      Name:  David Lontini
      Title: Chairman and Interim Chief Executive Officer

     

     

    4

     

    Get the next $CHEK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    8/9/21 6:35:25 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap downgraded by Dawson James with a new price target

    Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

    3/17/21 12:12:30 PM ET
    $CHEK
    Medical Electronics
    Health Care

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

    3/16/21 6:31:50 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    SEC Filings

    View All

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    11/4/25 5:16:13 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    10/16/25 5:15:01 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check-Cap Enter into Definitive Merger Agreement

    Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied

    9/12/25 5:39:51 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

    Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time

    6/4/25 7:00:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Financials

    Live finance-specific insights

    View All

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

    IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

    10/18/23 4:05:00 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

    8/16/23 5:08:47 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    View All

    Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

    Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

    11/28/23 11:56:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

    ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

    9/1/21 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D filed by Check-Cap Ltd.

    SC 13D - Check-Cap Ltd (0001610590) (Subject)

    4/1/24 9:26:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    12/18/23 6:07:13 AM ET
    $CHEK
    Medical Electronics
    Health Care